Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, Masakazu Haneda

ABSTRACT

Objective: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) possess multiple bioactive isoforms that are rendered non-insulinotropic by the enzyme dipeptidyl peptidase-4 (DPP-4). Recently, some ELISA kits have been developed to specifically measure “active” GIP and GLP-1, but it is unclear if these kits can accurately quantify all bioactive forms. Therefore, it remains uncertain to what extent treatment with a DPP-4 inhibitor boosts levels of biologically active GIP and GLP-1. Thus, we evaluated our novel receptor-mediated incretin bioassays in comparison to commercially available ELISA kits using plasma samples from healthy subjects before and after DPP-4 inhibitor administration.

Methods: We utilized cell lines stably co-transfected with human GIP or GLP-1 receptors and a cAMP-inducible luciferase expression construct for the bioassays and commercially available ELISA kits. Assays were tested with synthetic GIP and GLP-1 receptor agonists and plasma samples collected from subjects during a 75 g oral glucose tolerance test (OGTT) performed before or following 3-day administration of a DPP-4 inhibitor.

Results: A GIP isoform GIP(1–30)NH2 increased luciferase activity similarly to GIP(1–42) in the GIP bioassay but was not detectable by either a total or active GIP ELISA kit. During an OGTT, total GIP levels measured by ELISA rapidly increased from 0 min to 15 min, subsequently reaching a peak of 59.2 ± 8.3 pmol/l at 120 min. In contrast, active GIP levels measured by the bioassay peaked at 15 min (43.4 ± 6.4 pmol/l) and then progressively diminished at all subsequent time points. Strikingly, at 15 min, active GIP levels as determined by the bioassay reached levels approximately 20-fold higher after the DPP-4 inhibitor treatment, while total and active GIP levels determined by ELISA were increased just 1.5 and 2.1-fold, respectively. In the absence of DPP-4 inhibition, total GLP-1 levels measured by ELISA gradually increased up to 90 min, reaching 23.5 ± 2.4 pmol/l, and active GLP-1 levels determined by the bioassay did not show any apparent peak. Following administration of a DPP-4 inhibitor there was an observable peak of active GLP-1 levels as determined by the bioassay at 15 min after oral glucose load, reaching 11.0 ± 0.62 pmol/l, 1.4-fold greater than levels obtained without DPP-4 inhibitor treatment. In contrast, total GLP-1 levels determined by ELISA were decreased after DPP-4 inhibitor treatment.

Conclusion: Our results using bioassays indicate that there is a greater increase in plasma levels of bioactive GIP than GLP-1 in subjects treated with DPP-4 inhibitors, which may be unappreciated using conventional ELISAs.

Keywords: Receptor-mediated incretin bioassays; Glucose-dependent insulinotropic polypeptide; Glucagon-like peptide-1; Dipeptidyl peptidase-4
which are liberated from proglucagon via the action of PC 1/3 and released from L-cells mainly distributed in the lower small intestine and colon [1]. Both incretin hormones are rapidly cleared after secretion by dipeptidyl peptidase-4 (DPP-4) into truncated forms that are no longer insulinotropic [1]. Although recently developed ELISA kits may be able to detect active forms of GIP and GLP-1, it is unclear if these ELISAs can accurately quantify biologically active forms of the hormones because they are antibody based, measurements, and immunoreactivity may not always coincide with bioactivity of peptide hormones. Moreover, recent reports suggest that a shorter form GIP(1-30)NH₂ is secreted from the pancreas and the gut [2,3], and this form has insulinotropic activity almost equivalent to GIP(1-42) [2]. It was unclear, however, if this form is detectable by active GIP ELISAs.

DPP-4 inhibitors are widely used to improve glycemic control in patients with type 2 diabetes mellitus (T2DM), and they are a particularly effective treatment for non-obese diabetes patients in East Asia. More than 70% of Japanese patients treated with anti-diabetic drugs receive DPP4 inhibitors or GLP-1 mimetics and approximately 60% receive a DPP4 inhibitor as a conventional commercial active GIP ELISA kit (# 27201, IBL, Fujikawa, Japan) to assay the plasma samples for GIP and GLP-1 measurement by bioassay (GIP: 20-fold dilution, GLP-1: 10-fold dilution) with or without the sitagliptin administration.

For further details for the bioassays, stably selected co-transfected HEK293 cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (25 mmol/l glucose) with 10% (v/v) fetal bovine serum (FBS) (GIBCO, Tokyo, Japan), 100 IU/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Tokyo, Japan) at 37 °C in 5% CO₂. Cells were incubated overnight in 96-well plates (100,000 cells/well). Media was then replaced with samples or synthetic peptide standards (GIP bioassay: GIP(1-42), GIP(1-30)NH₂, GLP-1(7-36)NH₂, glucagon: 10⁻¹³-10⁻⁶ mol/l, GLP-1 bioassay: GLP-1(7-36)NH₂, GIP(1-42), GIP(1-30)NH₂ and glucagon: 10⁻¹³-10⁻⁹ mol/l) that were diluted in Krebs Ringer Buffer (KRB) (pH 7.4) containing 0.5% (w/v) bovine serum albumin (BSA) (Sigma—Aldrich, Tokyo, Japan) and incubated for 5 h at 37 °C in 5% CO₂. We diluted plasma samples with KRB before active GIP and GLP-1 measurement by bioassay (GIP: 20-fold dilution, GLP-1: 50-fold dilution). After incubation, we measured luciferase activity with the Bright-Glo Assay Kit (Promega, Madison, WI, USA) using a Thermo Scientific Appiaskan (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions and calculated the hormone concentrations as previously described [5].

2. MATERIAL AND METHODS

2.1. Subjects and study protocol

We recruited 10 non-diabetic subjects with informed consent for a 75 g OGTT male, age 32.3 ± 5.6 years, BMI 23.3 ± 5.6 kg/m², HbA1c 5.1 ± 0.28% (31.5 ± 2.7 mmol/mol); average ± SD. We performed a second OGTT after DPP-4 inhibitor treatment (sitagliptin: 100 mg/day for 3 days) in 5 subjects following the first OGTT and the second OGTT with or without DPP-4 inhibitor treatment (male, age 35.2 ± 6.3 years, BMI 23.3 ± 3.0 kg/m², HbA1c 5.1 ± 0.31% (31.8 ± 3.1 mmol/mol); average ± SD). The study was performed in accordance with the Declaration of Helsinki, and the research protocol was approved by the Research Ethics Committee of Asahikawa Medical University).

2.2. Study protocol

All subjects were fasted for 10–12 h before the OGTTs. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 min, and blood samples were collected at the same time points using blood collection tubes containing DPP-4 inhibitor (P800; BD, Tokyo, Japan).
In the GLP-1 bioassay, GLP-1(7-36)NH₂ increased luciferase activity in a concentration dependent manner. Glucagon induced luciferase activity at concentrations greater than approximately 10⁻¹¹ mol/l, consistent with prior studies demonstrating relatively low affinity binding of glucagon to GLP-1 receptors [6]. In contrast, GIP(1-42) did not increase luciferase activity in the GLP-1 bioassay (Figure 1B). The DPP-4 inhibitor sitagliptin did not significantly alter luciferase activity in the GIP bioassay (Figure S2).

3.2. The administration of a DPP-4 inhibitor markedly increased bioactive GIP levels after glucose load in non-diabetic subjects
During the OGTTs, blood glucose levels peaked at 30 min and insulin levels reached a peak at 30–60 min (Figure 2A and B). Total GIP levels did not significantly after luciferase activity in the GIP bioassay (Figure S2).

Figure 1: The receptor-mediated GIP bioassay detects both GIP(1-42) and GIP(1-30)NH₂. The responsiveness and specificity of (A) GIP and (B) GLP-1 receptor-mediated bioassays with GIP, GLP-1, and glucagon peptides. White triangles, GIP(1-42); white inverted triangles, GIP(1-30)NH₂; black triangles, GLP-1(7-36)NH₂; black inverted triangles, glucagon. Data are presented as mean ± SEM.

Figure 2: Active GIP levels by bioassay showed an apparent peak at 15 min during a 75 g OGTT. Blood glucose (A), plasma insulin (B), plasma active (bioassay), and total (ELISA) GIP (C) and GLP-1 (D) levels in samples collected at the indicated times during a 75 g OGTT (n = 10 in each group). For (C) and (D), white circles, total GIP; black circles, active GIP; white squares, total GLP-1; black squares, active GLP-1. Data are presented as mean ± SEM. *p < 0.05, ****p < 0.0001.
in the samples measured by ELISA rapidly increased from 0 to 15 min and subsequently gradually increased up to a peak at 120 min (59.2 ± 8.3 pmol/l; Figure 2C). In contrast, active GIP levels determined by the bioassay peaked at 15 min (43.4 ± 6.4 pmol/l; Figure 2C). Total GLP-1 levels as measured by ELISA increased to 30 min and remained at similar levels up to 120 min (23.4 ± 2.0 pmol/l; Figure 2D). Active GLP-1 levels by the bioassay did not show an apparent peak, averaging 7.9 ± 0.35 pmol/l (Figure 2D).

The three-day administration of a DPP-4 inhibitor tended to lower blood glucose levels during an OGTT but without statistical difference (Figure 3A). Postprandial plasma insulin levels were increased approximately 2-fold at several time points compared to before DPP-4 inhibitor administration (Figure 3B). The active GIP levels were markedly elevated at all time points in all 5 subjects following treatment with the DPP-4 inhibitor, but, given the variability, statistical significance was only achieved at two time points (Figure 3C). Active GIP levels measured using the bioassay at 15 min were approximately 20-fold greater than values at the same time point before DPP-4 inhibitor treatment (Figure 3C). In contrast, total GIP levels by ELISA at 15 min were 1.5-fold greater (Figure 3D) while active GIP levels determined by ELISA were 2.1-fold greater than values at the same time point before DPP-4 inhibitor treatment (Figure 3E). Administration of other DPP-4 inhibitors (linagliptin: 5 mg/day and vildagliptin: 100 mg/day) increased active GIP as determined by the bioassay during OGTT similarly to sitagliptin (data not shown).

Unlike active GIP, active GLP-1 levels by the bioassay were only modestly elevated after the DPP-4 inhibitor treatment from 0 to 120 min and increased by 1.4-fold at 15 min after oral glucose load (Figure 3F). In contrast, total GLP-1 levels as determined by ELISA were decreased after DPP-4 inhibitor treatment (Figure 3G).

4. DISCUSSION

Plasma GIP and GLP-1 levels are typically measured by ELISA, a highly sensitive immunological method to detect specific antigens. However, it can be difficult for these assays to distinguish antigens with similar epitopes. Indeed, it has been demonstrated that commercially available glucagon ELISA kits have cross-reactivity with glicentin and other proglucagon-derived peptides [7–9]. The specificity and sensitivity of commercially available kits for the analysis of GLP-1 levels also vary considerably [10]. Additionally, the immunological values obtained with these assays may not accurately reflect the total biological activity as some immunoreactive variants may not be bioactive, and some bioactive forms may not be immunoreactive. The receptor-mediated method we employed here reflects incretin receptor binding ability and intracellular signaling through cyclic AMP production. Therefore, the receptor-mediated bioassays may better reflect biological activity of intact incretin hormones than conventional immunological based methods. For example, we found that GLP-1, glucagon, GLP-2, oxyntomodulin, secretin and mini-glucagon (glucagon(19–29)) did not cross-react in the GIP bioassay, even at concentrations as high as 100 nM (Figure 1 and data not shown). Nevertheless, we cannot discount the possibility that there are fragments of GIP and GLP-1, such as the DPP-4 products GIP(3–42) and GLP-1(9–36)NH2, that may have biological actions mediated by non-cyclic AMP intracellular signaling pathways and thus not detected by our bioassays.

GIP is localized in gut K-cells with PC 1/3, which liberates the 42 amino acid mature form of GIP from Pro-GIP [3]. Recently, it was reported that Pro-GIP is processed to GIP(1–30)NH2 in pancreatic alpha cells and in the gut by PC2 [2,3] and demonstrated that GIP(1–30)NH2 possesses insulinotropic activity similar to GIP(1–42) [2]. DPP-4 exists as a...
soluble form in circulation [11] or a membrane bound form in many tissues including endocrine cells of the pancreatic islets [12]. Moreover, recent studies indicate that GIP is particularly susceptible to DPP-4 activity in hematopoietic and endothelial cells [13]. Therefore, circulating GIP(1–30)_NH₂ concentrations are likely very low in the absence of DPP-4 inhibitor treatment, because GIP(1–30)_NH₂ is anticipated to be rapidly cleaved by DPP-4 like GIP(1–42) [14]. In the absence of DPP-4 inhibitor treatment, there may be relatively large amounts of circulating GIP(3–30)_NH₂ with presently unappreciated biological actions. The administration of DPP-4 inhibitor may reduce GIP(1–30)_NH₂ inactivation, and thus GIP(1–30)_NH₂ may have contributed to the markedly elevated bioactive GIP levels we measured in subjects following administration of the DPP-4 inhibitor. While our GIP bioassay characterization excludes the possibility of significant contributions from major glucagon-related peptides, some of which are DPP-4 substrates, we cannot exclude the possibility that there are other peptides activating the GIP receptor once stabilized by 3 days of DPP-4 inhibitor treatment.

In this study, active GLP-1 levels by the bioassay were modestly elevated after the DPP-4 inhibitor treatment from 0 to 120 min. In contrast, total GLP-1 levels as determined by ELISA were decreased after DPP-4 inhibitor treatment. Our findings are similar to that of Nauck et al. who also demonstrated that DPP-4 inhibitor treatment increased active GLP-1 and reduced total GLP-1 levels [15]. It is reported that GLP-1(7–36)_NH₂ stimulates intestinal somatostatin release [16] and somatostatin inhibits GLP-1 secretion from the gut [17]. Consequently, an increase in active GLP-1 levels by DPP-4 inhibition could promote somatostatin secretion which ultimately reduces intestinal GLP-1 secretion. It is also possible that increased bioactive GIP levels might act to reduce GLP-1 levels, as GIP infusion has been reported to significantly decrease postprandial plasma GLP-1 levels during a mixed meal in humans [18].

During the OGTTs, DPP-4 inhibitor administration enhanced postprandial insulin levels and dramatically increased active GIP levels measured by bioassay. GIP stimulates insulin secretion and is reported to enhance glucagon release especially in the hypoglycemic state [19]. It is possible that in our studies with non-diabetic subjects treated with DPP-4 inhibitor, GIP-stimulated glucagon secretion might partially explain the modest reduction of glucose levels despite the hyperinsulinemia. DPP-4 inhibition may have also augmented the biological activity of glucagon [20], although the biological importance of DPP-4-mediated glucagon cleavage for glucagon action in humans remains to be clarified.

It has been reported that the insulinotropic action of GIP is severely diminished in patients with T2DM [21–23]. As a result, it is generally assumed that GIP contributes little to the therapeutic efficacy of DPP-4 inhibitors. Moreover, there was no added therapeutic benefit following the addition of a dipeptidyl peptidase-4 inhibitor to ongoing therapy with a GLP-1 receptor agonist, despite increased plasma levels of immunoreactive intact GIP (and GLP-1) [24]. However, administration of the GLP-1 receptor antagonist exendin(9–39) only blocks ~50% of the glucose lowering effect of DPP-4 inhibitor treatment in humans [15,25], suggesting that DPP-4-sensitive factors beyond circulating GLP-1 substantially contribute to the actions of DPP-4 inhibitors. In agreement, DPP-4 inhibitor treatment in mice with GLP-1 receptor knockout still increased plasma insulin levels and improved glucose tolerance similarly as in wildtype mice [26]. GIP is a likely candidate, because DPP-4 therapy is completely ineffective in mice with combined knockout of GIP and GLP-1 receptors, suggesting that extended activity of both GIP and GLP-1 accounts for the full glucose lowering actions of DPP-4 inhibitors [26,27]. Moreover, a unimolecular GLP-1/GIP co-agonist demonstrated enhanced antihyperglycemic and insulinotropic efficacy relative to selective GLP-1 agonists in diabetic rodents and humans [28]. Our findings of a particularly large increase in bioactive GIP levels in humans treated with DPP-4 inhibitors, combined with observations that administration of a GIP(1–30) analog can improve glycemic control in diabetic rodents [29], supports the notion that increased GIP bioactivity contributes significantly to the therapeutic benefit of DPP-4 therapy.

Our study was limited to assessing glucose-stimulated incretin responses in healthy subjects during an OGTT. However, incretin secretion is also simulated by fat ingestion [1]. Therefore, future studies should examine bioactive incretin responses to other nutrients too. In addition, there are miscellaneous reports with ELISAs indicating that plasma GIP and GLP-1 levels in subjects with T2DM are increased, comparable, or even decreased relative to those in healthy subjects [30,31]. The bioassays described here may be useful tools to measure bioactive incretin levels to resolve these discrepancies.

In conclusion, our studies suggest that ELISAs may typically underestimate the levels of bioactive incretins, particularly assays that do not detect GIP(1–30)_NH₂. Moreover, we find that DPP-4 inhibitor treatment has a much greater impact on plasma bioactive GIP levels than bioactive GLP-1 levels in healthy subjects. Therefore, the contribution of GIP to the therapeutic efficacy of DPP-4 inhibitor treatment warrants additional examination.

ACKNOWLEDGEMENTS

This research was supported in part by research grants from the Japan Diabetes Foundation (Incretin Research), the Japan Society for the Promotion of Science (JSPS; Grant-in-Aid for Scientific Research (C) #23591291), and Insulin Research Foundation (Novo Nordisk Pharma, Japan). YF also received scholarships from Eli Lilly, Pfizer and MSD. TJK gratefully acknowledges fellowship support from JSPS while on sabbatical at Kyoto University.

DUALITY OF INTEREST

The authors declare that there is no duality of interest associated with this manuscript.

CONTRIBUTION STATEMENT

TY, YF, Y Takeda, JH, HS, HK, Y Takiyama, YM, AA, TJK, and MH contributed to the study concept and design. TJK produced the HEK293 cell lines co-transfected with human forms of GIPR or GLP-1 receptor, and a cyclic AMP-inducible luciferase expression construct. TY and YF acquired the data. TY, YF, Takeda, JH, HS, HK, Y Takiyama, YM, AA, and MH analyzed and interpreted the data. TY, YF, and TJK drafted the manuscript. TY, YF, Takeda, JH, HS, HK, Y Takiyama, YM, AA, TJK, and MH reviewed the manuscript for important intellectual content. YF and MH are the guarantors of this work.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.molmet.2016.12.009.

REFERENCES

[1] Cho, Y.M., Merchant, C.E., Kieffer, T.J., 2012. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & Therapeutics 135: 247–278.
[2] Fujita, Y., Wideman, R.D., Asadi, A., Yang, G.K., Baker, R., Webber, T., et al., 2010. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet β-cells and promotes insulin secretion. Gastroenterology 138:1966–1975.

[3] Fujita, Y., Asadi, A., Yang, G.K., Kwon, Y.N., Kieffer, T.J., 2010. Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut. The American Journal of Physiology Gastrointestinal and Liver Physiology 298: G606–G614.

[4] Seino, Y., Kuwata, H., Yabe, D., 2016. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. Journal of Diabetes Investigation 7(Suppl 1):102–109.

[5] Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Atageldiyeva, K.K., Takiyama, Y., et al., 2016. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice. Diabetologia 59:533–541.

[6] Kieffer, T.J., Heller, R.S., Unson, C.G., Weir, G.C., Habener, J.F., 1996. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137:5119–5125.

[7] Weyer Albrechtsen, N.I., Hartmann, B., Veedelfd, S., Windfeld, J.A., Plamboeck, A., Bojesen-Møller, K.N., et al., 2014. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57:1919–1926.

[8] Bak, M.J., Albrechtsen, N.W., Pedersen, J., Hartmann, B., Christensen, M., Vilsbøll, T., et al., 2014. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology 170:529–538.

[9] Matsuo, T., Miyagawa, J., Kusunoki, Y., Miuchi, M., Ikawa, T., Akagami, T., et al., 2015. Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay. Journal of Diabetes Investigation 6:324.

[10] Omar, B.A., Liehau, L., Yamada, Y., Seino, Y., Marchetti, P., Ahtrén, B., 2014. Dipeptidyl peptide 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57:1867–1883.

[11] Mulvihill, E.E., Drucker, D.J., 2014. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine Reviews 35:992–1019.

[12] Nakamura, M., Imai, H., Yamada, Y., Seino, Y., Marchetti, P., Ahtrén, B., 2014. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57:1867–1883.

[13] Mulvihill, E.E., Varin, E.M., Gladman, B., Campbell, J.E., Ussher, J.R., Baggio, L.L., et al., 2016. Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis. Cell Metabolism. http://dx.doi.org/10.1016/j.cmet.2016.07.007. S1550–4131(16)30538-1. Epub Nov 4.

[14] Kieffer, T.J., McDanes, C.H., Pederson, R.A. 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585–3596.

[15] Nauck, M.A., Kind, J., Köthe, D.L., Holst, J.J., Deacon, C.F., Broschag, M., et al., 2016. Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9–39] as a GLP-1 receptor antagonist. Diabetes 65:2440–2447.

[16] Brubaker, P.L., Elendic, S., Greenberg, G.R., 1997. Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release. Endocrine 1:91–95.

[17] Hansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P.N., Holst, J.J., 2000. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology Endocrinology and Metabolism 278:E1010–E1018.

[18] Chia, C.W., Carlson, O.D., Kim, W., Shin, Y.K., Charles, C.P., Kim, H.S., et al., 2009. Exogenous glucose-dependent insulinotropic polypeptide worsens postprandial hyperglycemia in type 2 diabetes. Diabetes 58:1342–1349.

[19] Christensen, M., Vedtofte, L., Holst, J.J., Vilsbøll, T., Knop, F.K., 2011. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60:3103–3109.

[20] Psopoulou, J.A., Hinke, S.A., Pederson, R.A., Hoffmann, T., Rosche, F., Schlenzig, D., et al., 2001. Metabolism of glucagon by dipeptidyl peptide IV (CD26). Regulatory Peptides 93:133–141.

[21] Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W., 1993. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation 91:301–307.

[22] Elahi, D., McAloon-Dyke, M., Fukagawa, N.K., Menelli, G.S., Sclater, A.L., Minaker, K.L., et al., 1994. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides 51:63–74.

[23] Vilsbøll, T., Krarup, T., Madsbad, S., Holst, J.J., 2002. Defective activation of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45:1111–1119.

[24] Nauck, M.A., Kahle, M., Baranov, O., Deacon, C.F., Holst, J.J., 2016. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist tiragliflozin: a randomized controlled trial in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. http://dx.doi.org/10.1111/dob.12802. Epub Oct 6.

[25] Außinger, B.A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J.J., Vilsbøll, T., et al., 2012. Defining the role of GLP-1 in the enteroinsular axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 61:1079–1092.

[26] Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., et al., 2004. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucose-regulatory actions of DPP-IV inhibitors. Diabetes 53:1326–1335.

[27] Flock, G., Baggio, L.L., Longuet, C., Drucker, D.J., 2007. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56:3006–3013.

[28] Finan, B., Ma, T., Ottaway, N., Müller, T.O., Habegger, K.M., Hepner, K.M., et al., 2013. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine 5:ra151.

[29] Widenmaier, S.B., Kim, S.J., Yang, G.K., De Los Reyes, T., Nian, C., Asadi, A., et al., 2010. A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One 5:e9590.

[30] Calanna, S., Christensen, M., Holst, J.J., Laferrère, B., Gluud, L.L., Vilsbøll, T., et al., 2013. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 36:3352–3352.

[31] Calanna, S., Christensen, M., Holst, J.J., Laferrère, B., Gluud, L.L., Vilsbøll, T., et al., 2013. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56:965–972.